Elobixibat

CAS : 439087-18-0

Ref. 3D-PSA08718

Informations sur le produit

• Nom: Elobixibat
• Synonymes: Glycine, (2R)-N-[[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-, AZD 7806, Glycine, (2R)-N-[2-[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycyl-, (2R)-N-[2-[[3,3-Dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycylglycine

Description

Elobixibat is a drug that has been studied for its potential to treat cancer, chronic kidney disease and other diseases. It is a prodrug that is hydrolyzed in vivo to elobixibat acid, its active form. Elobixibat acid inhibits the sodium taurocholate co-transporting polypeptide (NTCP), which transports bile acids and sodium taurocholate into the small intestine. This inhibition leads to decreased bile acid levels and reduced symptoms of chronic kidney disease. Elobixibat acid also blocks the growth factor receptor tyrosine kinase c-Met, which can have therapeutic benefits for cancers such as colorectal cancer.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 695.9 g/mol
• Formule: C₃₆H₄₅N₃O₇S₂
• Degré de pureté: Min. 95%